Target intelligence / Profile preview

TM4SF18 antisense RNA 1 (TM4SF18-AS1)

Target
TM4SF18-AS1
Molecular classification
Long non-coding RNA (lncRNA), Antisense RNA, Competing endogenous RNA (ceRNA)
01

Overview

TM4SF18 antisense RNA 1 (TM4SF18-AS1) is a long non-coding antisense RNA, transcribed from the opposite strand of the TM4SF18 gene locus[4][6]. As a lncRNA, it does not encode a protein but carries out crucial regulatory functions in cancer biology, particularly through RNA-RNA and RNA-protein interactions. TM4SF18-AS1 exhibits upregulated expression in several cancer types, notably head and neck squamous cell carcinoma and gastric cancer[1][2]. Its biological role includes enhancing tumor cell proliferation, migration, and epithelial-mesenchymal transition, while suppressing apoptosis by facilitating stress granule formation. Mechanistically, TM4SF18-AS1 functions as a "molecular sponge" for specific microRNAs and interacts with various proteins to alter gene expression and cellular stress responses. Due to its oncogenic activity and upregulation in malignancies, TM4SF18-AS1 is considered a potential therapeutic target and biomarker in oncology, though it is a non-coding RNA and not a classical receptor or enzyme[1][2].

Other names
AC093001.1TM4SF18-AS1
02

Mechanism of action

Acts as a molecular sponge for specific microRNAs (e.g., miR-153-3p), thereby sequestering them and modulating downstream gene expression (such as LAMC1 in HNSCC). Interacts with proteins (e.g., heterogeneous nuclear ribonucleoprotein C, Pur-α, YB-1) to regulate cellular stress responses and support tumor cell survival. Promotes stress granule formation, inhibiting apoptosis in cancer cells. May recruit chromatin-associated proteins to modify gene expression epigenetically.

03

Biological functions

Gene expression regulation (via antisense interactions)Tumor cell proliferationMigration and invasionEpithelial-mesenchymal transition (EMT)Inhibition of apoptosis (via stress granule formation)Activation of interferon signaling (in some contexts)
04

Disease associations

Cancer (notably in head and neck squamous cell carcinoma, gastric cancer, hepatocellular carcinoma, lung cancer)Tumor progression and oncogenesis
05

Safety considerations

No drug-targeting safety data available.General challenges for lncRNA-targeted therapies include cellular delivery, off-target effects, and tissue-specific expression
06

Biomarkers

Upregulation in tumors (including HNSCC and gastric cancer) may serve as a diagnostic or prognostic biomarkerElevated expression may aid patient selection for targeted therapy trials or risk stratification

Beyond the preview

Go deeper on TM4SF18 antisense RNA 1 (TM4SF18-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TM4SF18 antisense RNA 1 (TM4SF18-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call